Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARVEY SEROTA

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1346264017
CMS profile
243035
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$52,608.99

220 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARVEY SEROTA

NPI 1346264017 · CMS profile ID 243035

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346264017?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARVEY SEROTA, NPI 1346264017, CMS profile ID 243035. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346264017?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HARVEY SEROTA, NPI 1346264017, CMS profile ID 243035. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346264017?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HARVEY SEROTA, NPI 1346264017, CMS profile ID 243035, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1346264017?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

220 matching records · $52,608.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 220 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 220.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vifor Pharma, Inc. $0.3207/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816117537 CMS
Novartis Pharmaceuticals Corporation $12.5007/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245757 CMS
Vifor Pharma, Inc. $15.2807/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816117415 CMS
SANOFI-AVENTIS U.S. LLC $17.5007/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843449081 CMS
Vifor Pharma, Inc. $17.8207/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816116681 CMS
Novartis Pharmaceuticals Corporation $0.7107/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245745 CMS
Merck Sharp & Dohme Corporation $13.0807/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848459931 CMS
Novartis Pharmaceuticals Corporation $13.9506/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245753 CMS
CVRx, Inc. $19.9506/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851087217 CMS
Esperion Therapeutics, Inc. $1,500.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400061 CMS
Esperion Therapeutics, Inc. $1,500.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400067 CMS
Amarin Pharma Inc. $15.7606/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815157825 CMS
AstraZeneca Pharmaceuticals LP $23.2006/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829697485 CMS
Janssen Pharmaceuticals, Inc $1,000.0006/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788135405 CMS
Novartis Pharmaceuticals Corporation $0.3706/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245737 CMS
Novartis Pharmaceuticals Corporation $10.1106/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245741 CMS
Esperion Therapeutics, Inc. $14.4806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400051 CMS
Esperion Therapeutics, Inc. $1.8906/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400053 CMS
Esperion Therapeutics, Inc. $1,500.0006/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400059 CMS
Novartis Pharmaceuticals Corporation $17.2106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245749 CMS
Amgen Inc. $19.5406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825347913 CMS
Novo Nordisk Inc $22.0506/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810934539 CMS
BOSTON SCIENTIFIC CORPORATION $24.1006/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777716127 CMS
AstraZeneca Pharmaceuticals LP $17.3106/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829472835 CMS
Esperion Therapeutics, Inc. $1,500.0006/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400045 CMS
Amarin Pharma Inc. $9.9406/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815157823 CMS
Vifor Pharma, Inc. $2.3606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816112011 CMS
CVRx, Inc. $18.0105/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851087215 CMS
ARBOR PHARMACEUTICALS, INC. $14.2105/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830931455 CMS
Esperion Therapeutics, Inc. $5.1805/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400035 CMS
Esperion Therapeutics, Inc. $1,500.0005/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400037 CMS
Esperion Therapeutics, Inc. $1,500.0005/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400043 CMS
Merck Sharp & Dohme Corporation $23.5305/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848542429 CMS
Novartis Pharmaceuticals Corporation $1.3305/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245729 CMS
Amgen Inc. $114.3905/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825347917 CMS
Merck Sharp & Dohme Corporation $18.0105/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848675515 CMS
Vifor Pharma, Inc. $16.6405/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816109083 CMS
Janssen Pharmaceuticals, Inc $11.3805/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788135433 CMS
Novartis Pharmaceuticals Corporation $15.9005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245733 CMS
Novartis Pharmaceuticals Corporation $13.3205/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813245725 CMS
AstraZeneca Pharmaceuticals LP $17.9605/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829270843 CMS
AstraZeneca Pharmaceuticals LP $11.1905/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829890591 CMS
Esperion Therapeutics, Inc. $10.9605/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400027 CMS
Esperion Therapeutics, Inc. $1,500.0005/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400029 CMS
Esperion Therapeutics, Inc. $3.1205/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838400021 CMS
SANOFI-AVENTIS U.S. LLC $18.7905/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843449073 CMS
Vifor Pharma, Inc. $15.1305/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816106575 CMS
Janssen Pharmaceuticals, Inc $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788135403 CMS
Janssen Pharmaceuticals, Inc $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788135407 CMS
Novo Nordisk Inc $17.2304/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810771709 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,999.51 108
PY2020 $54,271.31 158
PY2021 $52,608.99 220
PY2022 $200,283.86 277
PY2023 $179,157.84 225
PY2024 $135,188.35 175
PY2025 $113,219.59 119

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,710.63 1
PY2025 Principal investigator $825,669.99 278
PY2024 Recipient $960.67 1
PY2024 Principal investigator $855,022.55 15
PY2023 Recipient $5,091.38 1
PY2023 Principal investigator $802,872.17 32
PY2022 Recipient $45,680.08 5
PY2022 Principal investigator $881,871.06 114
PY2021 Recipient $18,810.34 7
PY2021 Principal investigator $358,058.54 491
PY2020 Principal investigator $1,010,996.63 1,139
PY2019 Principal investigator $1,602,601.88 621

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

279 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 12/30/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220669344
Principal investigator 1 Boehringer Ingelheim International GmbH $21.75 12/30/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220669346
Principal investigator 1 Boehringer Ingelheim International GmbH $4.35 12/30/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220669348
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/17/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220995954
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,015.45 12/17/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995984
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669782
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669784
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669786
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669788
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669790
Principal investigator 1 Boehringer Ingelheim International GmbH $1,729.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669792
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669794
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669796
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669798
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669800
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669802
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669804
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669806
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669808
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669810
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669812
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669814
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669816
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669818
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669820
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 12/15/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669822
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,015.45 12/12/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995986
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 12/01/2025 Non-covered Recipient Entity
St. Louis Heart and Vascular
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215507958
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,000.00 12/01/2025 Non-covered Recipient Entity
St. Louis Heart and Vascular
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215507963
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220669360
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669778
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669780
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669758
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669760
Principal investigator 1 Boehringer Ingelheim International GmbH $2,400.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669762
Principal investigator 1 Boehringer Ingelheim International GmbH $2,400.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669764
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669766
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669768
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669770
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669772
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669774
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669776
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 11/11/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995980
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/11/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995982
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220669358
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669754
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669756
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220669362
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220669364
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 10/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669824
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 10/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669826
Principal investigator 1 Boehringer Ingelheim International GmbH $21.00 10/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669828
Principal investigator 1 Boehringer Ingelheim International GmbH $2.82 10/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669830
Principal investigator 1 AstraZeneca Pharmaceuticals LP $56,183.92 10/22/2025 Non-covered Recipient Entity
ST LOUIS HEART AND VASCULAR PC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185555593
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $10,015.45 10/21/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995978
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669700
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669702
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669704
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669706
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669708
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669710
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669712
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669714
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669716
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669718
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669720
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669722
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669724
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669726
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669728
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669730
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669732
Principal investigator 1 Boehringer Ingelheim International GmbH $2,774.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669734
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669736
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669738
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669740
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669742
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669744
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669746
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669748
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669750
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 10/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669752
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,081.00 10/17/2025 Non-covered Recipient Entity
Saint Louis Heart And Vascular, PC
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) No dispute reported 06/30/2026 1235994099
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,300.00 10/02/2025 Non-covered Recipient Entity
ST LOUIS HEART AND VASCULAR PC
A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) No dispute reported 06/30/2026 1185555603
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220669350
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220669352
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 10/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220669354
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220669356
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669696
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669698
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 09/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669690
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 09/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669692
Principal investigator 1 Boehringer Ingelheim International GmbH $8.46 09/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669694
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $13,353.92 09/18/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995976
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $13,042.00 09/03/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Pc
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225409082
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669584
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669586
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 08/26/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669684
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 08/26/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669686
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 08/26/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669688
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $30,046.33 08/26/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995974
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 08/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669604
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 08/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669606
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 08/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669608
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 08/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669610
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669612
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669614
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 08/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669616
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669618
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669592
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669594
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669596
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669598
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669600
Principal investigator 1 Boehringer Ingelheim International GmbH $1,729.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669602
Principal investigator 1 Boehringer Ingelheim International GmbH $1,729.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669620
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669622
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669624
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669626
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669628
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669630
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669632
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669634
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669636
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669638
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669640
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669642
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669644
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669646
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669648
Principal investigator 1 Boehringer Ingelheim International GmbH $2,510.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669650
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669652
Principal investigator 1 Boehringer Ingelheim International GmbH $2,909.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669654
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669656
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669658
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669660
Principal investigator 1 Boehringer Ingelheim International GmbH $285.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669662
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669664
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669666
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669668
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669670
Principal investigator 1 Boehringer Ingelheim International GmbH $2,556.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669672
Principal investigator 1 Boehringer Ingelheim International GmbH $1,814.00 08/13/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669674
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669580
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669582
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 07/28/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669676
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 07/28/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669678
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 07/28/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669680
Principal investigator 1 Boehringer Ingelheim International GmbH $9.40 07/28/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669682
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669562
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669564
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669566
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669568
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669570
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669572
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669574
Principal investigator 1 Boehringer Ingelheim International GmbH $217.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669576
Principal investigator 1 Boehringer Ingelheim International GmbH $189.00 07/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669578
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669588
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669590
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220669338
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220669340
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 06/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220669342
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669552
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 06/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669554
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 06/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669556
Principal investigator 1 Boehringer Ingelheim International GmbH $11.31 06/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669558
Principal investigator 1 Boehringer Ingelheim International GmbH $8.46 06/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669560
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 06/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669530
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 06/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669532
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 06/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669534
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 06/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669536
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 06/20/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669538
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,513.26 06/11/2025 Non-covered Recipient Entity
ST LOUIS HEART AND VASCULAR PC
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185555599
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669494
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669496
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669498
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669500
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669502
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669504
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669506
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669508
Principal investigator 1 Boehringer Ingelheim International GmbH $217.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669510
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669512
Principal investigator 1 Boehringer Ingelheim International GmbH $1,270.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669514
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669516
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669518
Principal investigator 1 Boehringer Ingelheim International GmbH $1,270.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669520
Principal investigator 1 Boehringer Ingelheim International GmbH $2,211.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669522
Principal investigator 1 Boehringer Ingelheim International GmbH $217.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669524
Principal investigator 1 Boehringer Ingelheim International GmbH $217.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669526
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 06/04/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669528
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669490
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669492
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,346.20 05/29/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995968
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 05/28/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
Ph III HFrEF study No dispute reported 06/30/2026 1220995952
Principal investigator 1 Boehringer Ingelheim International GmbH $299.70 05/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669550
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669486
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669488
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $20,030.88 05/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995966
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669448
Principal investigator 1 Boehringer Ingelheim International GmbH $189.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669450
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669452
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669454
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669456
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669458
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669460
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669462
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669464
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669466
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669468
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669470
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669472
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669474
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669476
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669478
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669480
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669482
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 04/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669484
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 04/23/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669540
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 04/23/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669542
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 04/23/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669544
Principal investigator 1 Boehringer Ingelheim International GmbH $4.65 04/23/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669546
Principal investigator 1 Boehringer Ingelheim International GmbH $5.64 04/23/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669548
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,996.52 04/23/2025 Non-covered Recipient Entity
Saint Louis Heart And Vascular, PC
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) No dispute reported 06/30/2026 1235994097
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 04/08/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995970
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11,684.68 04/02/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995972
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669444
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669446
Principal investigator 1 Boehringer Ingelheim International GmbH $519.48 03/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669436
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 03/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669438
Principal investigator 1 Boehringer Ingelheim International GmbH $21.00 03/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669440
Principal investigator 1 Boehringer Ingelheim International GmbH $6.58 03/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669442
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 03/21/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995964
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669400
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669402
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669404
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669406
Principal investigator 1 Boehringer Ingelheim International GmbH $217.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669408
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669410
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669412
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669414
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669416
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669418
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 03/19/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669420
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11,684.68 03/11/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995962
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669394
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669396
Principal investigator 1 AstraZeneca UK Limited $152,173.96 02/27/2025 Non-covered Recipient Entity
ST LOUIS HEART AND VASCULAR PC
A Phase 2b Randomised,Double blind,Placebo controlled,Multi centre,Dose ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease WHO Group 2 No dispute reported 06/30/2026 1185555595
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 02/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669378
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 02/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669380
Principal investigator 1 Boehringer Ingelheim International GmbH $2,982.00 02/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669382
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 02/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669384
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 02/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669386
Principal investigator 1 Boehringer Ingelheim International GmbH $2,437.00 02/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669388
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 02/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669432
Principal investigator 1 Boehringer Ingelheim International GmbH $12.60 02/25/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669434
Recipient Novartis Pharmaceuticals Corporation $2,710.63 02/04/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293594
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669390
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669392
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669398
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 01/31/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995960
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,039.10 01/29/2025 Non-covered Recipient Entity
ST LOUIS HEART AND VASCULAR PC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185555601
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 01/29/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995956
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 01/29/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220995958
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 01/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669422
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 01/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669424
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 01/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669426
Principal investigator 1 Boehringer Ingelheim International GmbH $10.50 01/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669428
Principal investigator 1 Boehringer Ingelheim International GmbH $11.28 01/27/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669430
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 01/24/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669372
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,540.66 01/22/2025 Non-covered Recipient Entity
ST LOUIS HEART AND VASCULAR PC
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1185555605
Principal investigator 1 Boehringer Ingelheim International GmbH $475.00 01/22/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669366
Principal investigator 1 Boehringer Ingelheim International GmbH $2,298.00 01/22/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669368
Principal investigator 1 Boehringer Ingelheim International GmbH $1,751.00 01/22/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669370
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,406.43 01/08/2025 Non-covered Recipient Entity
ST LOUIS HEART AND VASCULAR PC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185555597
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669374
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
St Louis Heart And Vascular Cardiology-Christian Hospital Office
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220669376
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $20,096.15 01/01/2025 Non-covered Recipient Entity
ST. LOUIS HEART AND VASCULAR P.C.
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214125272